Hydrochlorothiazide ups risk of nonmelanoma skin cancer
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.
Researchers compared the patterns of HCTZ use between 80,162 NMSC patients and 1,603,345 age- and sex-matched controls. Those with SCC of the lip were excluded.
Conditional logistic regression analysis was used to calculate for the risk of basal cell carcinoma (BCC) or SCC with the frequency of HTCZ use. Adjustments were performed for potential confounder such as other medications and comorbidities.
The rate of high HCTZ usage in BCC patients was higher than in matched controls (2.7 vs 2.1 percent; odds ratio [OR], 1.29; 95 percent CI, 1.23 to 1.35). Similarly, significantly more SCC patients were high HCTZ users than matched controls (10.0 vs 2.8 percent; OR, 3.98; 3.68 to 4.31).
HCTZ use also showed a dose-response relationship with BCC and SCC, with those at the highest categories of exposure having the highest risks (OR for BCC, 1.54; 1.38 to 1.71; p<0.001 for trend; OR for SCC, 7.38; 6.32 to 8.60; p<0.001 for trend).
Similar trends were observed when the participants were grouped according to sex, age and tumour localization. Notably, none of the other diuretics and hypertensives showed significant relationships with the risk of SCC and BCC.